Very high serum CA 19-9 levels: A contraindication to pancreaticoduodenectomy?

Journal of Gastrointestinal Surgery

Volumn 13, Issue 10, 2009, Pages 1791-1797

  Turrini, O ^a   Schmidt, C M ^a,b   Moreno, J ^a   Parikh, P ^a   Matos, J M ^a   House, M G ^a   Zyromski, N J ^a   Nakeeb, A ^a   Pitt, H A ^a   Lillemoe, K D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CA 19 9; Pancreatic adenocarcinoma; Pancreatic cancer; Pancreaticoduodenectomy

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; DRUG CONTRAINDICATION; FEMALE; HUMAN; MALE; MIDDLE AGED; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PATHOLOGY; POSTOPERATIVE PERIOD; PREDICTION AND FORECASTING; PREOPERATIVE PERIOD; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 70449589304     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-009-0916-5     Document Type: Article

References (26)

1. Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, Tang L, Klimstra D, Allen PJ. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2008;12(4):701-706. doi:10.1007/s11605-007-0384-8.
2. Olivié D, Lepanto L, Billiard JS, Audet P, Lavallée JM. Predicting resectability of pancreatic head cancer with multi-detector CT. Surgical and pathologic correlation. JOP 2007;9;8(6):753-758.
3. Farma JM, Santillan AA, Melis M, Walters J, Belinc D, Chen DT, Eikman EA, Malafa M. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol. 2008;15(9):2465-2471. doi:10.1245/s10434-008-9992-0.
4. White R, Winston C, Gonen M, D'Angelica M, Jarnagin W, Fong Y, Conlon K, Brennan M, Allen P. Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. J Am Coll Surg. 2008;206(3):445-450. doi:10.1016/j.jamcollsurg.2007.09.021.
5. Karachristos A, Scarmeas N, Hoffman JP. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg. 2005;9:1286-1292. doi:10.1016/j.gassur.2005.06.008.
6. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266-270. doi:10.1016/j.ejso.2006.10.004.
7. Boeck S, Schulz C, Stieber P, Holdenrieder S, Weckbach S, Heinemann V. Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy. Onkologie. 2007;30(1-2):39-42. doi:10.1159/000097764.
8. Maithel SK, Maloney S, Winston C, Gönen M, D'Angelica MI, Dematteo RP, Jarnagin WR, Brennan MF, Allen PJ. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2008;15(12):3512-3520. doi:10.1245/s10434-008-0134-5.
9. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-del Castillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;20;24(18):2897-2902.
10. Montgomery RC, Hoffman JP, Riley LB, et al. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol. 1997;4:551-556. doi:10.1007/BF02305535.
11. Berger AC, Garcia M Jr, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26(36):5918-5922. doi:10.1200/JCO.2008.18.6288.
12. Zhang S, Wang YM, Sun CD, Lu Y, Wu LQ. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol 2008;21;14(23):3750-3753.
13. Smith RA, Ghaneh P, Sutton R, et al. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg. 2008;12(8):1422-1428. doi:10.1007/s11605-008-0554-3.
14. Halloran CM, Ghaneh P, Connor S, et al. Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy. Br J Surg. 2008;95(4):453-459. doi:10.1002/bjs.6043.
15. Ong SL, Garcea G, Thomasset SC, et al. Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma. J Gastrointest Surg. 2008;12(6):1068-1073. doi:10.1007/s11605-007-0422-6.
16. Berger AC, Meszoely IM, Ross EA, et al. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004;11(7):644-649. doi:10.1245/ASO.2004.11.025.
17. Nakao A, Oshima K, Nomoto S, Takeda S, Kaneko T, Ichihara T, Kurokawa T, Nonami T, Takagi H. Clinical usefulness of CA-19-9 in pancreatic carcinoma. Semin Surg Oncol. 1998;15:15-22. doi:10.1002/(SICI)1098-2388(199807/08)15:1<15::AID-SSU4>3.0.CO;2-Z .
18. House MG, Yeo CJ, Cameron JL, Campbell KA, Schulick RD, Leach SD, Hruban RH, Horton KM, Fishman EK, Lillemoe KD. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg. 2004;8(3):280-288. doi:10.1016/j.gassur.2003.12.011.
19. Nieto J, Grossbard ML, Kozuch P. Metastatic pancreatic cancer 2008: is the glass less empty. Oncologist. 2008;13(5):562-576. doi:10.1634/theoncologist.2007-0181, Review.
20. Magnani JL, Nilsson B, Brockhaus M, et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopenteose II. J Biol Chem. 1982;257:14365-14369.
21. Ritts RE, Pitt HA. CA 19-9 in pancreatic cancer. Surg Oncol Clin N Am. 1998;7:93-100.
22. Heinemann V, Boeck S. Perioperative management of pancreatic cancer. Ann Oncol. 2008;19(Suppl 7):vii273-vii278. doi:10.1093/annonc/mdn450.
23. Yamaguchi K, Enjoji M, Tsuneyoshi MJ. Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. Surg Oncol. 1991;47(3):148-154. doi:10.1002/jso.2930470303.
24. Nitsche M, Horstmann O, Christiansen H, Hermann RM, Hess CF, Becker H, Pradier O, Schmidberger H. Chemoradioimmunotherapy with 5-fluorouracil, cisplatin and interferon-alpha in pancreatic and periampullary cancer: results of a feasibility study. Cancer Radiother. 2008;12(8):817-821. doi:10.1016/j.canrad.2008.09.009.
25. Sanchez SE, Trevino JG. Current adjuvant and targeted therapies for pancreatic adenocarcinoma. Curr Med Chem. 2008;15(17):1674-1683. doi:10.2174/092986708784872348, Review.
26. Hernandez JM, Cowgill SM, Al-Saadi S, Collins A, Ross SB, Cooper J, Villadolid D, Zervos E, Rosemurgy A. CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg. 2009;13(2):349-353. doi:10.1007/s11605-008-0696-3.